BioSpace News Archive

This week money went towards more advanced rounds of financing for drugs and technology that have already shown a lot of promises.

89bio reported positive topline results from ENTRIGUE Phase II trial of pegozafermin in patients with severe hypertriglyceridemia.

Although the company promised strong sales-based resources for the launch of dry eye drug Tyrvaya, the streamlining plan will include laying off up to 50 employees.

As the nation reacts to the overturning of Roe v. Wade, pharma companies must address the changes in demand for drugs and services, all while navigating increasingly muddy legal waters.

McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2023 financial results after market close on Wednesday, August 3, 2022.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2022.

The work focuses on assessing the compounds’ ability to beneficially modulate intrinsic beta cell stress pathways involved in T1D progression.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2022 on Thursday, June 30, 2022.

Merit Medical Systems, Inc., a leading global manufacturer and marketer of healthcare technology, celebrated the completion of a xeriscape landscaping project at its South Jordan headquarters with Utah Governor Spencer J. Cox. Nearly three acres of grass has been replaced, reducing water intensive plantings by approximately 75%.

MediciNova, Inc., today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast).